New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis
Wolters Kluwer Showcases Innovative Culture and Software Development Prowess with 4th Annual Code Games Event
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Aaron’s, Inc. Investors
TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
GenSight Biologics to Present GS010 At the 2017 Annual Meeting of the American Association of Neurology
Among the thousands of small-company stocks, these are the most popular among analyst-recommended small-cap funds.
Small caps have reached the top of their cycle, manager Eric Cinnamond says. He’s hoarding cash for when the market turns.